Display options
Cite
Ünlü C, Erdogan G, Aydogan T, et al. Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy. J Ophthalmic Vis Res. 2016;11(1):61-5doi: 10.4103/2008-322X.180700.
Ünlü, C., Erdogan, G., Aydogan, T., Sezgin Akcay, B. I., Kardes, E., Kiray, G. A., & Bozkurt, T. K. (2016). Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy. Journal of ophthalmic & vision research, 11(1), 61-5. https://doi.org/10.4103/2008-322X.180700
Ünlü, Cihan, et al. "Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy." Journal of ophthalmic & vision research vol. 11,1 (2016): 61-5. doi: https://doi.org/10.4103/2008-322X.180700
Ünlü C, Erdogan G, Aydogan T, Sezgin Akcay BI, Kardes E, Kiray GA, Bozkurt TK. Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy. J Ophthalmic Vis Res. 2016 Jan-Mar;11(1):61-5. doi: 10.4103/2008-322X.180700. PMID: 27195087; PMCID: PMC4860989.
Copy Download .nbib Format: NLM
Share it on

J Ophthalmic Vis Res. 2016 Jan-Mar;11(1):61-5. doi: 10.4103/2008-322X.180700.

Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy.

Journal of ophthalmic & vision research

Cihan Ünlü, Gurkan Erdogan, Tugba Aydogan, Betul Ilkay Sezgin Akcay, Esra Kardes, Gulunay Akcali Kiray, Tahir Kansu Bozkurt

Affiliations

  1. Department of Ophthalmology, Ümraniye Training and Research Hospital, Istanbul, Turkey.

PMID: 27195087 PMCID: PMC4860989 DOI: 10.4103/2008-322X.180700

Abstract

PURPOSE: To compare the outcomes of treatment with intravitreal bevacizumab (IVB) versus observation in central serous chorioretinopathy (CSCR).

METHODS: In a retrospective comparative study, records of 45 patients with CSCR were reviewed. Twenty-two patients received IVB (1.25 mg/0.05 ml) while 23 subjects were observed. All subjects underwent measurement of best corrected visual acuity (BCVA) and intraocular pressure (IOP), dilated fundus examination and optical coherence tomography (OCT) imaging at baseline and follow up visits. Outcome measures included central macular thickness (CMT) and BCVA in logarithm of minimum angle of resolution (logMAR) notations.

RESULTS: Mean age was 44.1 ± 9.3 (range: 24 to 64) years and mean follow-up period was 10.4 ± 11.2 (range: 3 to 43; median: 6) months. All patients demonstrated resolution of neurosensory detachment and improvement in visual acuity. At final visit, there was no significant difference in mean CMT between the IVB and observation groups (275 vs 284 μm, P> 0.05). Mean baseline logMAR visual acuity was 0.38 ± 0.24 in the IVB group which improved to 0.24 ± 0.31 at final follow-up (P = 0.011); mean baseline logMAR visual acuity was 0.42 ± 0.28 in the observation group and improved to 0.12 ± 0.18 (P = 0.001). Visual improvement was more marked in the observation group (0.30 vs 0.14 logMAR, P< 0.05) and mean final visual acuity was also significantly better (P = 0.05).

CONCLUSION: There was no significant difference between IVB injection and observation in terms of anatomical outcomes of treatment for CSCR. In terms of visual outcomes, observation was superior to IVB injection.

Keywords: Central Serous Chorioretinopathy; Intravitreal Bevacizumab (Avastin); Macular Thickness; Observation

References

  1. Ophthalmology. 2008 Oct;115(10 ):1756-65 - PubMed
  2. Retina. 2006 May-Jun;26(5):495-511 - PubMed
  3. Int Ophthalmol. 1986 Apr;9(1):37-41 - PubMed
  4. Am J Ophthalmol. 2005 Jan;139(1):87-99 - PubMed
  5. Arch Ophthalmol. 1994 Aug;112(8):1057-62 - PubMed
  6. Curr Eye Res. 2010 Feb;35(2):91-8 - PubMed
  7. Int Ophthalmol. 1995;19(2):77-82 - PubMed
  8. Invest Ophthalmol Vis Sci. 2006 Jan;47(1):377-85 - PubMed
  9. Br J Ophthalmol. 2003 Dec;87(12 ):1453-8 - PubMed
  10. Nature. 2005 Sep 22;437(7058):497-504 - PubMed
  11. Am J Ophthalmol. 1967 Mar;63(3):Suppl:1-139 - PubMed
  12. Retina. 2007 Nov-Dec;27(9):1168-73 - PubMed
  13. Am J Ophthalmol. 2002 Jun;133(6):787-93 - PubMed
  14. Jpn J Ophthalmol. 2009 Jan;53(1):52-6 - PubMed
  15. Retina. 2010 Jan;30(1):100-6 - PubMed
  16. Klin Monbl Augenheilkd. 1983 Jun;182(6):549-51 - PubMed
  17. Acta Ophthalmol. 2008 Mar;86(2):126-45 - PubMed
  18. Bull Soc Belge Ophtalmol. 2002;(284):39-44 - PubMed
  19. Ophthalmology. 2002 Oct;109(10):1834-7 - PubMed
  20. Ophthalmology. 1989 Jun;96(6):854-9 - PubMed
  21. N Engl J Med. 2011 May 19;364(20):1897-908 - PubMed
  22. Am J Ophthalmol. 2007 May;143(5):887-9 - PubMed
  23. Ophthalmologica. 2009;223(5):343-7 - PubMed
  24. Ophthalmologica. 2011;225(1):37-40 - PubMed
  25. Ophthalmic Surg Lasers. 1997 Aug;28(8):693-7 - PubMed
  26. Ann Ophthalmol. 1977 Dec;9(12):1567-72 - PubMed
  27. Br J Ophthalmol. 1988 Nov;72(11):829-34 - PubMed
  28. Eye (Lond). 2011 Dec;25(12):1635-40 - PubMed
  29. Am J Ophthalmol. 2002 Mar;133(3):373-85 - PubMed
  30. Am J Ophthalmol. 1996 Jan;121(1):26-34 - PubMed
  31. Retina. 2002 Feb;22(1):19-24 - PubMed
  32. Retina. 2009 Nov-Dec;29(10):1469-73 - PubMed
  33. Br J Ophthalmol. 2006 Nov;90(11):1344-9 - PubMed
  34. Ophthalmologica. 2009;223(4):263-8 - PubMed
  35. Ophthalmology. 2002 Sep;109(9):1723-5 - PubMed
  36. Retina. 2010 Oct;30(9):1465-71 - PubMed
  37. Am J Ophthalmol. 2004 May;137(5):826-33 - PubMed
  38. Korean J Ophthalmol. 2010 Jun;24(3):155-8 - PubMed
  39. Ophthalmology. 2006 Mar;113(3):363-372.e5 - PubMed

Publication Types